AKF gains sponsorship for its kidney disease educational campaigns
Click Here to Manage Email Alerts
The American Kidney Fund announced it gained sponsorship for its education and awareness campaigns for complement 3 glomerulopathy and IgA nephropathy from Novartis Pharmaceuticals Corporation, according to a press release.
The AKF intends to design a webpage about complement 3 glomerulopathy (C3G), which will detail the disease and offer a downloadable guide for patients to learn the best conversations to have with their doctors about C3G. Additionally, the campaign will include a video series sharing patient viewpoints and perspectives.
As for the IgA nephropathy (IgAN) campaign, AKF plans to expand its current webpage about the condition with information about nutrition and mental health resources. A guide similar to that for C3G will also be available on the webpage.
“Novartis is proud to support these campaigns as part of our long-standing commitment to slowing kidney disease progression and improving patient outcomes by working to address the barriers often impeding health care,” Victor Bulto, president of Innovative Medicines U.S. at Novartis, said in the release. “These two rare kidney diseases, C3G and IgAN, can place a substantial hardship on people with these conditions and their caregivers, and this partnership is an important step in helping reduce those physical and emotional burdens.”
Both campaigns for C3g and IgAN contribute to the AKF goal to provide resources to patients with rare kidney-related diseases. As Healio previously reported, the AKF launched the Unknown Causes of Kidney Disease Project to improve understanding of how undiagnosed causes of kidney diseases can impact patients.
Read more about
Click Here to Manage Email Alerts